Literature DB >> 10918478

A radiation-controlled molecular switch for use in gene therapy of cancer.

S D Scott1, B Marples, J H Hendry, L S Lashford, M J Embleton, R D Hunter, A Howell, G P Margison.   

Abstract

Ionising radiation induces the expression of a number of radiation-responsive genes and there is current interest in exploiting this to regulate the expression of exogenous therapeutic genes in gene therapy strategies for cancer. However, the radiation-responsive promoters used in these approaches are often associated with low and transient levels of therapeutic gene expression. We describe here a novel radiation-triggered molecular switching device based on promoter elements from the radiation-responsive Egr-1 gene and the cre-LoxP site-specific recombination system of the P1 bacteriophage. Using this system, a single, minimally toxic dose of radiation induced cre-mediated excision of a lox-P flanked stop cassette in a silenced expression vector and this resulted in amplified levels of CMV-promoter-driven expression of the exogenous tumour-sensitising gene, HSV-tk. This strategy could be used in combination with targeted delivery and tumour-specific promoters to elicit the tumour-targeted and prolonged expression of a variety of tumour-sensitising genes and provide an unprecedented level of control and tumour selectivity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10918478     DOI: 10.1038/sj.gt.3301223

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  9 in total

Review 1.  Plasmid engineering for controlled and sustained gene expression for nonviral gene therapy.

Authors:  Ethlinn V B van Gaal; Wim E Hennink; Daan J A Crommelin; Enrico Mastrobattista
Journal:  Pharm Res       Date:  2006-05-26       Impact factor: 4.200

2.  Construction of targeted plasmid vector pcDNA3.1-Egr.1p-p16 and its expression in pancreatic cancer JF305 cells induced by radiation in vitro.

Authors:  Hong-Bing Ma; Xi-Jing Wang; Zheng-Li Di; Hui Xia; Zheng Li; Jie Liu; Jie Ma; Hua-Fen Kang; Cong-Mei Wu; Ming-Hua Bai
Journal:  World J Gastroenterol       Date:  2007-08-21       Impact factor: 5.742

3.  Demonstration of Tightly Radiation-Controlled Molecular Switch Based on CArG Repeats by In Vivo Molecular Imaging.

Authors:  Ya-Ju Hsieh; Luen Hwu; Chien-Chih Ke; Ai-Lin Huang; Fu-Du Chen; Shyh-Jong Wu; Sharon Chia-Ju Chen; Yong-Hua Zhao; Ren-Shyan Liu
Journal:  Mol Imaging Biol       Date:  2015-12       Impact factor: 3.488

4.  Radiation-inducible silencing of uPA and uPAR in vitro and in vivo in meningioma.

Authors:  Venkateswara Rao Gogineni; Arun Kumar Nalla; Reshu Gupta; Bharathi Gorantla; Meena Gujrati; Dzung H Dinh; Jasti S Rao
Journal:  Int J Oncol       Date:  2010-04       Impact factor: 5.650

Review 5.  Current status of tumor radiogenic therapy.

Authors:  Feng-Ling Min; Hong Zhang; Wen-Jian Li
Journal:  World J Gastroenterol       Date:  2005-05-28       Impact factor: 5.742

6.  An oncolytic adenovirus regulated by a radiation-inducible promoter selectively mediates hSulf-1 gene expression and mutually reinforces antitumor activity of I131-metuximab in hepatocellular carcinoma.

Authors:  Yan Zhang; Lin Fang; Quan'an Zhang; Qin Zheng; Jinlong Tong; Xiaohui Fu; Xiaoqing Jiang; Changqing Su; Junnian Zheng
Journal:  Mol Oncol       Date:  2012-11-07       Impact factor: 6.603

Review 7.  Novel therapeutic strategies in prostate cancer management using gene therapy in combination with radiation therapy.

Authors:  Spencer J Collis; Kevin Khater; Theodore L DeWeese
Journal:  World J Urol       Date:  2003-08-13       Impact factor: 3.661

8.  Transcriptional Targeting in Cancer Gene Therapy.

Authors:  Tracy Robson; David G. Hirst
Journal:  J Biomed Biotechnol       Date:  2003

9.  Evaluation of p21 promoter for interleukin 12 radiation induced transcriptional targeting in a mouse tumor model.

Authors:  Urska Kamensek; Gregor Sersa; Maja Cemazar
Journal:  Mol Cancer       Date:  2013-11-12       Impact factor: 27.401

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.